George F. Horner III
President and Chief Executive Officer

Mr. Horner joined Prestwick in August 2006 and is our President and Chief Executive Officer. Most recently he worked at Vicuron Pharmaceuticals, Inc. where he served as president, chief executive officer and a director from 1996 until the company was acquired by Pfizer, Inc. in September 2005. Prior to Vicuron, Mr. Horner worked as a corporate vice president at Ligand Pharmaceuticals from 1993 to 1995, and before that, he spent nearly two decades in a variety of executive positions at Abbott Laboratories. He is a member of the board of directors of Endo Pharmaceuticals, Inc.

Martin Stogniew, Ph.D.
Executive Vice President, Chief Technology Officer

Martin Stogniew, Ph.D. joined Prestwick in August 2007 as Executive Vice President, Chief Technology Officer. Dr. Stogniew joins Prestwick most recently from Zelos Therapeutics, where he was Executive Vice President of Development responsible for pre-clinical, regulatory and patent development. Previously, Dr. Stogniew worked at Vicuron Pharmaceuticals as Executive Vice President of Scientific Affairs from 2001 to 2005 before it was bought by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, he served as Chief Scientific Officer at Next Pharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciences at MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and a B.S. pharmacy degree from the University of Maryland.

Robert S. Radie
Executive Vice President & Chief Business Officer

Mr. Radie joined Prestwick in August 2007 and serves as our Executive Vice President and Chief Business Officer.  Mr. Radie has over 22 years of experience in the pharmaceutical and biotechnology industry. Mr. Radie joins Prestwick most recently from Morphotek, Inc., where he was Vice President of Project Management and Chief Business Officer, and helped lead the successful acquisition of Morphotek by Eisai. Prior to Morphotek, he was Senior Vice President of Strategic Projects and Planning at Vicuron Pharmaceuticals, where he was responsible for marketing and sales, corporate strategy, and business development. He played an integral role in the Pfizer acquisition of Vicuron Pharmaceuticals for $1.9 billion. Before joining Vicuron, Mr. Radie spent his professional career in positions of increasing responsibility at Eli Lilly and Company.  During his tenure at Eli Lilly he managed several successful product launches and led national sales forces, most recently as the director of sales for Eli Lilly's critical care division.  He also contributed to the shaping of Eli Lilly's reimbursement strategy which was designed to ensure that hospital products gained timely formulary approval.  Prior to that, as director of sales for Eli Lilly's diabetes top performing business unit, Mr. Radie launched three new products, including Actos® and Humalog Mix 75/25®, and led a significant expansion of that sales force.  He also played an important role in the launch of Prozac® and Zyprexa®, Eli Lilly's two leading neuroscience drugs.  He holds a Bachelor of Science degree in chemistry from Boston College.

David A. Stamler, M.D.
Chief Scientific Officer and Head of Development

Dr. Stamler joined Prestwick as our Chief Scientific Officer and Head of Development in June, 2005. Before joining Prestwick, Dr. Stamler had 12 years of experience within the pharmaceutical industry. From 2003 to 2005 he was the Senior Global Project Leader for Central Nervous System (CNS) Diseases for Fujisawa Pharmaceutical Company, where he led global development activities for two drugs to treat Alzheimer’s Disease and a drug for acute stroke. From 2003 to 2005, he also served as the Vice President of Research and Development, Medical Sciences for its U.S. subsidiary, Fujisawa Healthcare, Inc., chairing the Protocol Review Committee, and serving on the Global Development Investment Committee. From 1997 to 2003, Dr. Stamler held positions of increasing responsibility for the Fujisawa Research Institute of America, Inc. He began his tenure as Medical Director and culminating as Vice President, a position he held from 2000 to 2003 and also chairing the CNS Therapeutic Area Committee. At Abbott Laboratories, Dr. Stamler was the Director of Clinical Research, Pharmaceutical Products for the International Division from 1995 to 1997. Key activities during this period included medical oversight of European registration for the HIV protease inhibitor ritonavir, strategic planning with sales and marketing to defend existing businesses, oversight of clinical research at the country level and new product evaluation for in-licensing. From 1993 to 1995, Dr. Stamler was Associate Medical Director, Anti-infectives, with responsibility for Phase 1-4 trials in respiratory infection and H. pylori-associated gastrointestinal infection.

Dr. Stamler received his B.A. and M.D. from the University of Chicago. He completed his Residency in Internal Medicine at Temple University Hospital as well as Fellowships in Infectious Diseases and Clinical Microbiology at the University of Pennsylvania. He is board certified in Internal Medicine and Infectious Diseases.

He is a founding member of the American Society of Experimental NeuroTherapeutics (ASENT), a member of the American Academy of Neurology and the American College of Physicians. He has authored publications in peer-reviewed scientific journals for CNS, gastrointestinal, respiratory and inflammatory diseases.